Meningococcal Disease

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

EMA withdrawal · 2025-02-05
EMA Withdrawn: Penbraya (Neisseria meningitidis group A polysaccharide conjugated to tetanus toxoid;Neisseria meningitidis group C polysaccharide conjugated to tetanus toxoid;Neisseria meningitidis group W polysaccharide conjugated to tetanus toxoid;Neisseria meningitidis group Y polysaccharide conjugated to tetanus toxoid;Neisseria meningitidis group B fHBP protein subfamily A;Neisseria meningitidis group B fHBP protein subfamily B) — Pfizer Europe MA EEIG
EMA has withdrawn the marketing authorization for Penbraya, a meningococcal vaccine developed by Pfizer Europe MA EEIG. The withdrawal took …
CLINICAL_TRIALS withdrawal · 2016-12-01
Clinical Trial Update: Safety of One Dose of Meningococcal ACWY Conjugate Vaccine in Subjects 2 Years of Age and Older
The clinical trial evaluating the safety of a single-dose meningococcal ACWY conjugate vaccine in subjects aged 2 years and older has been w…
CLINICAL_TRIALS withdrawal · 2013-02-20
Clinical Trial Update: A Case-control Study of the Efficacy of a New Serogroup A Meningococcal Conjugate Vaccine (MenAfriVac) in Mali and Niger
Status update indicating that the case-control trial evaluating the efficacy of MenAfriVac in Mali and Niger has been withdrawn. The study a…